Abstracts Archive - Page 2508 of 2607 - ACR Meeting Abstracts

Abstract Number: 1454 • 2012 ACR/ARHP Annual Meeting
Characterization of Renal Mononuclear Phagocyte Populations in Murine SLE Nephritis
Ranjit Sahu¹, Ramalingam Bethunaickan² and Anne Davidson¹, ¹Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Macrophages and dendritic cells contribute to renal damage in chronic renal diseases including lupus nephritis. However owing to their multiple phenotypic and functional variations,…
Abstract Number: 1455 • 2012 ACR/ARHP Annual Meeting
Mitochondrial Dysfunction in the Liver of Lupus-Prone MRL/Lpr Mice Prior to Disease Onset
Zachary A. Oaks¹, Tiffany Telarico² and Andras Perl³, ¹SUNY, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Liver dysfunction, characterized by serum elevation of liver enzymes, is detectable in 20% of patients with systemic lupus erythematosus (SLE.) Males had a higher…
Abstract Number: 1416 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus
Mariana Postal¹, Aline T. Lapa¹, Nailu A. Sinicato¹, Karina Peliçari¹, Lilian Costallat² and Simone Appenzeller³, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil, ³Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Elevated serum levels of tumor necrosis factor alpha (TNF-α) have been reported in patients with major depressive disorder and in patients with depression in…
Abstract Number: 1417 • 2012 ACR/ARHP Annual Meeting
Favorable Response to Belimumab At Three Months
Katrina M. Shum¹, Jill P. Buyon², H. Michael Belmont¹, Andrew G. Franks Jr.³, Richard Furie⁴, Diane L. Kamen⁵, Susan Manzi⁶, Michelle Petri⁷, Rosalind Ramsey-Goldman⁸, Chung-E Tseng¹, Ronald F. van Vollenhoven⁹, Daniel Wallace¹⁰ and Anca Askanase¹, ¹NYU School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Dermatology & Medicine (Rheumatology), New York University, New York, NY, ⁴North Shore-LIJ Health System, Lake Success, NY, ⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹The Karolinska Institute, Stockholm, Sweden, ¹⁰Cedars-Sinai/UCLA, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use…
Abstract Number: 1418 • 2012 ACR/ARHP Annual Meeting
Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Anca D. Askanase¹, Katrina M. Shum¹, Stan Kamp², Fredonna C. Carthen², Teresa J. Aberle³ and J.T. Merrill², ¹NYU School of Medicine, New York, NY, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Disease activity measures used in SLE clinical studies, including the SLEDAI (SLE Disease Activity Index) and BILAG (British Isles Lupus Assessment Group) index are…
Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Renata Baronaite Hansen¹ and Søren Jacobsen², ¹Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…
Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
A. Lois-Iglesias¹, J. Ishorari² and D.A. Isenberg², ¹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in patients with SLE treated with B cell…
Abstract Number: 1421 • 2012 ACR/ARHP Annual Meeting
Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease
Ioana Ruiz-Arruza¹, D. D. Gladman¹, Dominique Ibanez² and Murray B. Urowitz², ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Studies in the last 20 years have demonstrated that antimalarials (AM) prevent flares, protect from damage accrual, reduce the risk of thrombosis and increase…
Abstract Number: 1422 • 2012 ACR/ARHP Annual Meeting
Clinical Associations of Anti-Smith Antibodies in Profile: A Multiethnic Lupus Cohort
Yesenia C. Santiago-Casas¹, Luis M. Vila¹, Gerald McGwin Jr.², Ryan S. Cantor², Michelle Petri³, Rosalind Ramsey-Goldman⁴, John D. Reveille⁵, Robert P. Kimberly⁶, Graciela S. Alarcon⁷ and Elizabeth E. Brown⁸, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁶Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Anti-Smith (anti-Sm) antibodies are highly specific for systemic lupus erythematosus (SLE) and have an important value in the diagnosis of this disease. However, whether…
Abstract Number: 1423 • 2012 ACR/ARHP Annual Meeting
Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Amir Haddad¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The trigger for a thrombotic in patients with antiphospholipid antibodies is unknown. Thrombocytopenia is among the most common clinical manifestations of the Antiphospholipid antibody…
Abstract Number: 1424 • 2012 ACR/ARHP Annual Meeting
Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)
José M. Pego-Reigosa¹, Íñigo Rúa-Figueroa², Francisco J. López-Longo³, María Galindo⁴, Jaime Calvo-Alén⁵, Alejandro Olivé⁶, Loreto Horcada⁷, Esther Uriarte⁸, Eva Tomero⁹, Ana Sánchez-Atrio¹⁰, Carlos Montilla¹¹, José Rosas¹², Antonio Fernández-Nebro¹³, Paloma Vela¹⁴, Mercedes Freire¹⁵, Lucía Silva¹⁶, Elvira Díez-Álvarez¹⁷, Carlos Marras¹⁸, Antonio Zea¹⁹, Javier Narváez²⁰, Jose Luis Marenco²¹, Monica Fernández de Castro²², Olaia Fernánde-Berrizbeitia²³, Marian Gantes²⁴ and Celia Erausquin²⁵, ¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ²Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ⁵Reumatología, Hospital Sierrallana, Torrelavega, Spain, ⁶Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Reumatología, Hospital de Navarra, Spain, ⁸Reumatología, Hospital de Donosti, Donosti, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Reumatología, Hospital Príncipe de Asturias, Madrid, Spain, ¹¹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Reumatología, Hospital de Marina Baixa, Alicante, Spain, ¹³Reumatología, Hospital Carlos Haya, Malaga, Spain, ¹⁴Reumatología, Hospital General de Alicante, Alicante, Spain, ¹⁵Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Rheumatology, Hospital de Guadalajara, Guadalajara, Spain, ¹⁷Reumatología, Hospital de León, León, Spain, ¹⁸Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁹Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁰Reumatología, Hospital de Bellvitge, Barcelona, Spain, ²¹Rheumatology, Hospital de Valme, Seville, Spain, ²²Hospital Puerta del Hierro, Madrid, Spain, ²³Reumatología, Hospital de Basurto, Basurto, Spain, ²⁴Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ²⁵Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain
Background/Purpose: Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Immunosuppression, comorbidities, and the disease itself makes patients with SLE…
Abstract Number: 1425 • 2012 ACR/ARHP Annual Meeting
Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE
Gregg J. Silverman¹, John Jung², Ehtisham Akhter³, Michelle Petri⁴ and Caroline Grönwall², ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: SLE patients are at risk for diverse organ systems involvement, which increases the challenges for diagnosis and predictions for the development of specific clinical…
Abstract Number: 1426 • 2012 ACR/ARHP Annual Meeting
The Clinical Relevance of a “False Negative” Enzyme Linked Immunoassay: Which Antinuclear Antibody Screening Test Is Preferred by Rheumatologists in an Integrated Health System?
Rachita Bansal¹, David Bulbin², Alfred E. Denio³, Sandi Kelsey⁴ and Harold Harrison⁴, ¹Dept of Rheumatology, Geisinger Medical Center, Danville, PA, ²Dept of General Internal Medicine, Geisinger Medical Center, Danville, PA, ³Dept of Rheumatology, Geisinger Health System, Danville, PA, ⁴Dept of Pathology, Geisinger Medical Center, Danville, PA
Background/Purpose: Historically, Immunofluorescence Assay (IFA) methodology has been the gold standard for ANA screening. Most clinical laboratories in recent years utilize the Enzyme Linked Immunoassay…
Abstract Number: 1427 • 2012 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant?
Juan G. Ovalles-Bonilla¹, Julia Martínez-Barrio¹, Javier Lopez-Longo¹, Inmaculada de la Torre¹, Carlos Gonzalez Fernandez¹, María Montoro Álvarez¹, Francisco Aramburu¹, Carolina Marin¹, Lina Martinez-Estupiñan¹, Juan C. Nieto², Michelle Hinojosa¹, Natalia Bello¹, Indalecio Monteagudo¹ and Luis Carreño¹, ¹Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ²Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Classically, late onset Systemic Lupus Erythematosus (SLE) has been described as a milder variant of the disease. The objective of this study is to…
Abstract Number: 1428 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus
Evelyne Vinet¹, Mohammed Kaouache², Christian A. Pineau³, Ann E. Clarke⁴, Caroline P. Gordon⁵, Robert W. Platt⁶ and Sasha Bernatsky², ¹McGill University Health Center, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁶McGill University, Montreal, QC, Canada
Background/Purpose: SLE can cause considerable morbidity during pregnancy. Although several studies have evaluated foetal outcome in lupus pregnancy, very few have examined the long-term outcome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].